Friday August 27, London

01.00 - 23.59
WCO-IOF-ESCEO
08.00 - 09.00
NON-SPONSORED SYMPOSIA
08.00 - 09.00
AVAILABLE INDUSTRY BREAKFAST SYMPOSIUM
08.00 - 09.00
AVAILABLE INDUSTRY BREAKFAST SYMPOSIUM
09.00 - 10.30
SCIENTIFIC SESSION I
Chairpersons: ‣ Cyrus Cooper, ‣ Jean‑Yves Reginster
09.00
Plenary Lecture 1
‣ Management of musculoskeletal disease from cradle to grave Cyrus Cooper
09.30
Oral communication selected from abstracts
10.30 - 12.10
SCIENTIFIC SESSION II
Chairpersons: ‣ John A. Kanis, ‣ René Rizzoli
10.30
Presentation of the ESCEO-IOF Herbert Fleisch Medal
10.35
Presentation of the IOF President's Award
10.40
Plenary Lecture 2
‣ Building bone strength with anabolic agents Michael R. McClung
11.10
Oral communication selected from abstracts
12.15 - 13.45
AVAILABLE INDUSTRY SATELLITE LUNCH SYMPOSIUM
14.00 - 15.00
MEET-THE-EXPERT SESSIONS
Transgender medicine, bone and muscle
‣ Jean‑Marc Kaufman
Impact of glucocorticoids on bone and muscle
‣ Evelien Gielen
HIV and bone
‣ Emmanuel Biver
Is screening of osteoporosis useful?
‣ E. M. Curtis
14.00 - 15.00
Poster Viewing Session I
14.00 - 15.10
Oral presentation of selected posters
14.00 - 15.00
Educational Lecture
‣ Dietary patterns and fracture risk Stefania Maggi
14.00 - 15.00
ESCEO Symposium
‣ Determinants of the differences between the ESCEO and OARSI 2019 guidelines for the management of knee osteoarthritis
Chairpersons: ‣ Ali Mobasheri, ‣ Jean‑Yves Reginster
‣ Similarities and differences between the OARSI and ESCEO guidelines for the management of knee osteoarthritis Tim McAlindon
‣ How can we explain the differences between the OARSI and ESCEO guidelines for the management of knee osteoarthritis? Nigel K. Arden
‣ Discussion (Leader: Olivier Bruyère) All
14.00 - 15.00
Update of the ESCEO recommendations for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia
Chairpersons: ‣ Charlotte Beaudart, ‣ Roger A. Fielding
‣ Introduction Alfonso Cruz Jentoft
‣ Patients to be included in clinical trials assessing the safety and efficacy of new chemical entities aiming at the treatment of sarcopenia Mario Miguel Rosa
‣ Primary and secondary endpoints for clinical trials assessing the safety and efficacy of new chemical entities aiming at the treatment of sarcopenia Andrea Laslop
‣ Discussion (Leader : Andrea Trombetti): All participants of the Working Group
‣ Conclusion Jürgen Bauer
15.00 - 17.00
SCIENTIFIC SESSION III
Chairpersons: ‣ Radmila Matijevic, ‣ Manju Chandran
15.00
Plenary Lecture 3
‣ Management of bone disease in cancer Robert E. Coleman
15.30
Oral communication selected from abstracts
16.30
Plenary Lecture 4
‣ Thyroid, bone and cartilage G Williams
15.00 - 16.45
COMMITTEE OF NATIONAL SOCIETIES SPECIAL PLENARY SESSION
15.45
Presentation of the IOF Committee of National Societies Medal
17.00 - 18.30
AVAILABLE INDUSTRY SATELLITE SYMPOSIUM
17.00 - 18.30
AVAILABLE INDUSTRY SATELLITE SYMPOSIUM